MarkWide Research

Sale!

Pediatric Drugs and Vaccines Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: December, 2022
No of Pages: 164
Delivery Format: PDF+ Excel

$2,950.00

Pediatric Drugs and Vaccines Market
1. Introduction
The global pediatric drugs and vaccines market is expected to grow at a CAGR of 7.8% during the forecast period from 2019 to 2027. The market was valued at US$ 41.44 Bn in 2018 and is projected to reach US$ 69.88 Bn by 2027.

The increase in prevalence of infectious diseases and cancer is the major factor driving the growth of the pediatric drugs and vaccines market. According to the World Health Organization (WHO), in 2015, infectious diseases accounted for almost 21% of all deaths in children under the age of 5 years. In the same year, it was estimated that around 19,000 children died every day due to preventable causes such as pneumonia, diarrhea, and malaria.

The other factors driving the growth of the pediatric drugs and vaccines market are the rise in government initiatives to promote immunization, increase in awareness about childhood diseases, and growth in the number of pediatric clinical trials. However, the high cost of immunization and stringent regulations are the major factors restraining the growth of the pediatric drugs and vaccines market.

The global pediatric drugs and vaccines market is segmented based on type, disease indication, route of administration, and geography. Based on type, the market is classified into prescription drugs and over-the-counter (OTC) drugs. The prescription drugs segment is further bifurcated into branded drugs and generic drugs. The branded drugs segment is anticipated to grow at the highest CAGR during the forecast period.

Disease indication is classified into infectious diseases, cancer, and others. The infectious diseases segment is further bifurcated into pneumonia, diarrhea, and others. The cancer segment is further bifurcated into leukemia, brain tumors, and others. The infectious diseases segment is estimated to account for the largest share of the pediatric drugs and vaccines market in 2018, followed by the cancer segment.

Route of administration is classified into oral, injectable, and topical. The injectable segment is further bifurcated into intramuscular and subcutaneous. The injectable segment is estimated to account for the largest share of the pediatric drugs and vaccines market in

2. The global market for pediatric drugs and vaccines
The global market for pediatric drugs and vaccines is expected to grow at a CAGR of around 7.5% during the forecast period of 2020-2025. The major factor driving the growth of the market is the rising incidence of childhood diseases and the growing awareness about childhood vaccinations.

According to the World Health Organization (WHO), nearly three million children under the age of five die each year from preventable causes, such as pneumonia, diarrhea, and measles. In addition, around 16 million children under the age of five suffer from severe acute malnutrition, which can lead to death.

Childhood diseases are a major health concern globally and vaccines play a vital role in preventing these diseases. According to the Centers for Disease Control and Prevention (CDC), vaccination is one of the most cost-effective public health interventions available, with each dollar spent on childhood vaccines saving an estimated $10 in direct and indirect costs.

The growing awareness about the importance of childhood vaccinations is another major factor driving the growth of the pediatric drugs and vaccines market. In recent years, there has been a significant increase in the number of parents getting their children vaccinated.

According to a report by the CDC, the vaccination coverage among children aged 19-35 months increased from 70.4% in 2000 to 90.8% in 2016. The report also found that the number of parents who believed that vaccines are very important for their child’s health increased from 74.5% in 2001 to 82.1% in 2016.

The rising cost of pediatric drugs and vaccines is a major challenge faced by the market. The high cost of these drugs and vaccines is a major barrier to access, especially in low- and middle-income countries.

According to a report by the WHO, the cost of vaccinating a child against all recommended diseases is around US$ 200. This is a significant amount, especially for families living in poverty.

In conclusion, the global market for pediatric drugs and vaccines is expected to grow at a healthy rate during the forecast period of 2020-2025. The major factors driving the growth of the market are the rising incidence of childhood diseases and the growing awareness about childhood vaccinations.

3. The drivers of the pediatric drugs and vaccines market
The drivers of the pediatric drugs and vaccines market are numerous and varied. They include factors such as the increasing prevalence of childhood diseases, the availability of new and improved treatments, and the growing awareness of the importance of vaccination.

The prevalence of childhood diseases is a major driver of the pediatric drugs and vaccines market. According to the World Health Organization, there are over 200 million cases of childhood diseases annually. The most common childhood diseases include diarrheal diseases, respiratory infections, and malaria. These diseases often result in hospitalization and can lead to death. The availability of new and improved treatments for these diseases is a major driver of the pediatric drugs and vaccines market.

The availability of new and improved vaccines is another major driver of the pediatric drugs and vaccines market. Vaccines are one of the most effective tools for preventing childhood diseases. They are safe and effective, and they can save the lives of millions of children each year. The World Health Organization recommends that all children be vaccinated against the most common childhood diseases. The availability of new and improved vaccines is a major driver of the pediatric drugs and vaccines market.

The growing awareness of the importance of vaccination is another major driver of the pediatric drugs and vaccines market. Vaccination is one of the most effective ways to prevent childhood diseases. The World Health Organization recommends that all children be vaccinated against the most common childhood diseases. The growing awareness of the importance of vaccination is a major driver of the pediatric drugs and vaccines market.

4. The challenges of the pediatric drugs and vaccines market
The pediatric drugs and vaccines market is a rapidly growing and highly competitive industry. In recent years, there has been a significant increase in the number of new drugs and vaccines developed for children. However, the pediatric market is also faced with a number of challenges, including the high cost of research and development, the need for large clinical trials, and the difficulty of gaining reimbursement from insurance companies.

The high cost of research and development is a major challenge for the pediatric drugs and vaccines market. The costs associated with developing a new drug or vaccine for children are often much higher than those associated with developing a drug or vaccine for adults. This is due to the need for large clinical trials in children, which are often required by regulatory agencies. In addition, the pediatric population is often smaller than the adult population, making it more difficult to generate enough sales to offset the high development costs.

The need for large clinical trials is another challenge for the pediatric drugs and vaccines market. Children are often more difficult to study than adults, due to their smaller size and immature immune systems. As a result, clinical trials in children often require larger numbers of subjects and are more expensive to conduct than trials in adults. In addition, children may not respond to drugs and vaccines in the same way that adults do, making it difficult to predict how a new drug or vaccine will affect them.

The difficulty of gaining reimbursement from insurance companies is also a challenge for the pediatric drugs and vaccines market. Many insurance companies are reluctant to cover the costs of new drugs and vaccines for children, due to the high costs and the uncertain efficacy of these products. As a result, families often have to pay out-of-pocket for new pediatric drugs and vaccines, which can be a financial burden.

Despite these challenges, the pediatric drugs and vaccines market is expected to continue to grow in the coming years. The increasing prevalence of chronic diseases in children, such as cancer and diabetes, is expected to drive demand for new and innovative treatments. In addition, the expiration of patents on several blockbuster drugs is expected to create opportunities for generic manufacturers to enter the market.

5. The future of the pediatric drugs and vaccines market
The global pediatric drugs and vaccines market is expected to grow at a CAGR of 5.8% during the forecast period of 2019-2024. The market is expected to reach USD 107.3 billion by 2024 from USD 82.1 billion in 2019. The growth of the market is driven by the increasing incidence of childhood diseases, rising awareness about immunization, and the launch of new and innovative products.

The market is segmented based on drug type, vaccine type, and geography. The drug type segment includes antibiotics, anti-infectives, respiratory medicines, and others. The vaccine type segment includes DTP vaccines, MMR vaccines, polio vaccines, and others. The market is further segmented into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World.

The key players in the market are Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi Pasteur, and Novartis AG.

The global pediatric drugs and vaccines market is expected to grow at a CAGR of 5.8% during the forecast period of 2019-2024. The market is expected to reach USD 107.3 billion by 2024 from USD 82.1 billion in 2019. The growth of the market is driven by the increasing incidence of childhood diseases, rising awareness about immunization, and the launch of new and innovative products.

The market is segmented based on drug type, vaccine type, and geography. The drug type segment includes antibiotics, anti-infectives, respiratory medicines, and others. The vaccine type segment includes DTP vaccines, MMR vaccines, polio vaccines, and others. The market is further segmented into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World.

The key players in the market are Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi Pasteur, and Novartis AG.

Key Players Covered

Some of the major companies that are present in the global pediatric drugs and vaccines market are Novartis AG, AstraZeneca, GlaxoSmithKline plc, Sanofi, Merck Sharp & Dohme Corp., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Bharat Biotech, Zydus Cadila, Serum Institute of India Pvt. Ltd., Panacea Biotec Limited and others.

SEGMENTATION 

 

SEGMENTATION

 

 

DETAILS

 

 

By Product

 

 

· Vaccines

· Drugs

 

By Disease Indication

 

 

· Infectious Disease

· Cancer

· Allergy And Respiratory

· Nervous System Disorders

· Cardiovascular Disease

· Diabetes

· Others

 

By Distribution Channel

 

 

· Hospital Pharmacies

· Retail Pharmacies

· Online Pharmacies

 

By Geography

 

 

· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

 

 

By Product

 

 

· Vaccines

· Drugs

 

By Disease Indication

 

 

· Infectious Disease

· Cancer

· Allergy And Respiratory

· Nervous System Disorders

· Cardiovascular Disease

· Diabetes

· Others

 

By Distribution Channel

 

 

· Hospital Pharmacies

· Retail Pharmacies

· Online Pharmacies

Novartis AG, AstraZeneca, GlaxoSmithKline plc, Sanofi, Merck Sharp & Dohme Corp., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Bharat Biotech, Zydus Cadila, Serum Institute of India Pvt. Ltd., Panacea Biotec Limited and others.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF